European Pharmaceutical Manufacturer spoke to Ashu Tandon, CCO, Aragen at CPHI Frankfurt about their 2026 predictions for the company.
1. We’re seeing early signs of biotech funding stabilising. What trends are you observing on the ground — both for biologics and small-molecule programmes — and how is that influencing the type of projects coming your way?